Takeda Pharmaceutical Company Limited has been experiencing several ebbs and flows recently. It has been identified as a cheap pharmaceutical stock for purchase according to short sellers and its stocks have been acquired by various investors such as
XY Capital Ltd and
Natixis Advisors LLC. Despite some setbacks in financial performance and a decrease in FY23 operating profit, the company remains attractive, with a strong shareholder base. Takeda's revenue growth has been noticed by analysts and it has been described as a
potential value investment. Furthermore, Takeda’s recent developments towards sustainable pharmaceutical innovation and FDA approval for
Eohilia are promising. The company is partaking in significant partnerships and deals such as a $2.2 billion deal for Alzheimer therapy and a licensing agreement with
Torrent Pharmaceuticals. It has also launched
Voltapraz, a drug in India, in collaboration with Sun Pharma. Despite facing a downturn in stock price, Takeda remains a preferred choice among many investors.
Takeda Pharmaceutical Stocks News Analytics from Mon, 09 Jan 2017 08:00:00 GMT to Sat, 07 Sep 2024 09:07:05 GMT -
Rating 4
- Innovation 6
- Information 8
- Rumor -2
